Probucol therapy improves long-term (>10-year) survival after complete revascularization: A propensity analysis

Atherosclerosis

Volumn 220, Issue 2, 2012, Pages 463-469

  Kasai, Takatoshi ^a   Miyauchi, Katsumi ^a   Kubota, Naozumi ^a   Kajimoto, Kan ^a   Amano, Atsushi ^a   Daida, Hiroyuki ^a  

^a JUNTENDO UNIVERSITY   (Japan)

Author keywords

Anti oxidant; Atherosclerosis; Coronary artery disease; Probucol

Indexed keywords

PROBUCOL;

ADULT; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; CORONARY ARTERY RECANALIZATION; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROPENSITY SCORE; RISK ASSESSMENT;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ANTICHOLESTEREMIC AGENTS; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; FEMALE; HUMANS; JAPAN; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROBUCOL; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84855956085     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.09.051     Document Type: Article

References (30)

1. Kita T., Nagano Y., Yokode M., et al. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA 1987, 84:5928-5931.
2. Carew T.E., Schwenke D.C., Steinberg D. Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 1987, 84:7725-7729.
3. Siveski-Iliskovic N., Kaul N., Singal P.K. Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation 1994, 89:2829-2835.
4. Fruebis J., Gonzalez V., Silvestre M., Palinski W. Effect of probucol treatment on gene expression of VCAM-1, MCP-1, and M-CSF in the aortic wall of LDL receptor-deficient rabbits during early atherogenesis. Arterioscler Thromb Vasc Biol 1997, 17:1289-1302.
5. Brasen J.H., Koenig K., Bach H., et al. Comparison of the effects of alpha-tocopherol, ubiquinone-10 and probucol at therapeutic doses on atherosclerosis in WHHL rabbits. Atherosclerosis 2002, 163:249-259.
6. Sawayama Y., Shimizu C., Maeda N., et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia, Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol 2002, 39:610-616.
7. Tardif J.C., Cote G., Lesperance J., et al. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty, Multivitamins and Probucol Study Group. N Engl J Med 1997, 337:365-372.
8. Yokoi H., Daida H., Kuwabara Y., et al. Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the probucol angioplasty restenosis trial. J Am Coll Cardiol 1997, 30:855-862.
9. Daida H., Kuwabara Y., Yokoi H., et al. Effect of probucol on repeat revascularization rate after percutaneous transluminal coronary angioplasty (from the Probucol Angioplasty Restenosis Trial [PART]). Am J Cardiol 2000, 86:A559. 550-552.
10. 10 Tardif J.C., Gregoire J., Schwartz L., et al. Effects of AGI-1067 and probucol after percutaneous coronary interventions. Circulation 2003, 107:552-558.
11. 11 Watanabe K., Sekiya M., Ikeda S., Miyagawa M., Hashida K. Preventive effects of probucol on restenosis after percutaneous transluminal coronary angioplasty. Am Heart J 1996, 132:23-29.
12. 12 Yamashita S., Matsuzawa Y. Where are we with probucol: a new life for an old drug?. Atherosclerosis 2009, 207:16-23.
13. Sasahara M., Raines E.W., Chait A., et al. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol, I. Is the extent of atherosclerosis related to resistance of LDL to oxidation?. J Clin Invest 1994, 94:155-164.
14. Franceschini G., Sirtori M., Vaccarino V., et al. Mechanisms of HDL reduction after probucol. Changes in HDL subfractions and increased reverse cholesteryl ester transfer. Arteriosclerosis 1989, 9:462-469.
15. McPherson R., Hogue M., Milne R.W., Tall A.R., Marcel Y.L. Increase in plasma cholesteryl ester transfer protein during probucol treatment. Relation to changes in high density lipoprotein composition. Arterioscler Thromb 1991, 11:476-481.
16. Chiesa G., Michelagnoli S., Cassinotti M., et al. Mechanisms of high-density lipoprotein reduction after probucol treatment: changes in plasma cholesterol esterification/transfer and lipase activities. Metabolism 1993, 42:229-235.
17. Ishigami M., Yamashita S., Sakai N., et al. High-density lipoproteins from probucol-treated patients have increased capacity to promote cholesterol efflux from mouse peritoneal macrophages loaded with acetylated low-density lipoproteins. Eur J Clin Invest 1997, 27:285-292.
18. Rinninger F., Wang N., Ramakrishnan R., Jiang X.C., Tall A.R. Probucol enhances selective uptake of HDL-associated cholesteryl esters in vitro by a scavenger receptor B-I-dependent mechanism. Arterioscler Thromb Vasc Biol 1999, 19:1325-1332.
19. Hirano K., Ikegami C., Tsujii K., et al. Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism. Arterioscler Thromb Vasc Biol 2005, 25:2422-2427.
20. Miida T., Seino U., Miyazaki O., et al. Probucol markedly reduces HDL phospholipids and elevated prebeta1-HDL without delayed conversion into alpha-migrating HDL: putative role of angiopoietin-like protein 3 in probucol-induced HDL remodeling. Atherosclerosis 2008, 200:329-335.
21. Yamashita S., Bujo H., Arai H., et al. Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb 2008, 15:292-303.
22. Jones E.L., Weintraub W.S. The importance of completeness of revascularization during long-term follow-up after coronary artery operations. J Thorac Cardiovasc Surg 1996, 112:227-237.
23. McLellan C.S., Ghali W.A., Labinaz M., et al. Association between completeness of percutaneous coronary revascularization and postprocedure outcomes. Am Heart J 2005, 150:800-806.
24. Walldius G., Erikson U., Olsson A.G., et al. The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol 1994, 74:875-883.
25. Tardif J.C., McMurray J.J., Klug E., et al. Effects of succinobucol (AGI-1067) after an acute coronary syndrome: a randomised, double-blind, placebo-controlled trial. Lancet 2008, 371:1761-1768.
26. Kunsch C., Luchoomun J., Grey J.Y., et al. Selective inhibition of endothelial and monocyte redox-sensitive genes by AGI-1067: a novel antioxidant and anti-inflammatory agent. J Pharmacol Exp Ther 2004, 308:820-829.
27. McCord J.M. The evolution of free radicals and oxidative stress. Am J Med 2000, 108:652-659.
28. Kasai T., Miyauchi K., Kajimoto K., Kubota N., Kurata T., Daida H. Influence of diabetes on >10-year outcomes after percutaneous coronary intervention. Heart Vessels 2008, 23:149-154.
29. Viskin S., Justo D., Halkin A., Zeltser D. Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis 2003, 45:415-427.
30. Shah B.R., Laupacis A., Hux J.E., Austin P.C. Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. J Clin Epidemiol 2005, 58:550-559.